Mathias Kroll joins InProTher as the new CEO
InProTher is very proud to annnounce that we have hired Mathias Kroll as the company’s new CEO.
Mathias Kroll has got twelve years of research experience, split between the academic and biopharmaceutical sectors, and fourteen years of commercial experience mostly from business development but also from marketing in the pharmaceutical and vaccines industries. Mathias has previously held senior positions in Bayer, Sanofi, UCB, GSK, and Bavarian Nordic, and has studied and worked in different European countries, USA, and Japan. Mathias’ deal making experience includes all types of transactions of relevance in the pharma industry, including strategic alliances, licensing, options, M&A and other capital transactions, supply, collaborations, and grants.
In GSK Vaccines and Bavarian Nordic, he managed the business aspects of corporate portfolios of active immunotherapies against chronic disease and cancer. He holds a Ph.D. obtained for a thesis in Viral Immunology at Pasteur Institute (Paris), a M.B.A. from IMD (Lausanne), a diploma in virology (Pasteur Institute) and two M.Sc. from the University of Düsseldorf in chemistry and biology, respectively, following theses at UNC-Chapel Hill, and at University of Düsseldorf. His current assignments are CEO of InProTher ApS and Director of Abarceo Pharma.